Steroid-refractory ulcerative colitis treated with corticosteriods, metronidazole and vancomycin: A case report

BMC Gastroenterology

Volumn 5, Issue , 2005, Pages

  Miner, Jonathan ^a,b   Gillan, M Monem ^b   Alex, Philip ^a,b   Centola, Michael ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CIPROFLOXACIN; CORTICOSTEROID; MESALAZINE; METRONIDAZOLE; PREDNISONE; VANCOMYCIN; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; STEROID;

ADULT; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BODY WEIGHT DISORDER; CASE REPORT; CLOSTRIDIUM DIFFICILE; COLON BIOPSY; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; FECES ANALYSIS; FEVER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAVENOUS ADMINISTRATION; LABORATORY TEST; MALE; NAUSEA; PHYSICAL EXAMINATION; RHEUMATOLOGY; ULCERATIVE COLITIS; VOMITING; CLOSTRIDIUM INFECTION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG RESISTANCE; MICROBIOLOGY;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS, ULCERATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALE; METRONIDAZOLE; PREDNISONE; STEROIDS; VANCOMYCIN;

EID: 25444478906     PISSN: 1471230X     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-5-3     Document Type: Article

References (30)

1. Bolton RP, Sherriff RJ, Read AE: Clostridium difficile associated diarrhoea: a role in inflammatory bowel disease? Lancet 1980, 1:383-4.
2. Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT: Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985, 26:1380-4.
3. Trnka YM, LaMont JT: Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology 1981, 80:693-6.
4. Peppercorn MA: Are antibiotics useful in the management of nontoxic severe ulcerative colitis? J Clin Gastroenterol 1993, 17:14-7.
5. Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, Vuoristo M, Valtonen VV, Miettinen TA: Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 1998, 115:1072-8.
6. Chapman RW, Selby WS, Jewell DP: Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 1986, 27:1210-2.
7. Papadakis KA, Tung JK, Binder SW, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA: Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001, 96:2137-42.
8. Rachima C, Maoz E, Apter S, Thaler M, Grossman E, Rosenthal T: Cytomegalovirus infection associated with ulcerative colitis in immunocompetent individuals. Postgrad Med J 1998, 74:486-9.
9. Begos DG, Rappaport R, Jain D: Cytomegalovirus infection masquerading as an ulcerative colitis flare-up: case report and review of the literature. Yale J Biol Med 1996, 69:323-8.
10. Sambol SP, Merrigan MM, Lyerly D, Gerding DN, Johnson S: Toxin gene analysis of a variant strain of Clostridium difficile that causes human clinical disease. Infect Immun 2000, 68:5480-7.
11. Bond F, Payne G, Borriello SP, Humphreys H: Usefulness of culture in the diagnosis of Clostridium difficile infection. Eur J Clin Microbiol Infect Dis 1995, 14:223-6.
12. Siarakas S, Tambosis E, Robertson GJ, Funnell GR, Bradbury R, Gottlieb T: Comparison of two commercial enzyme immunoassays with cytotoxicity assay and culture for the diagnosis of Clostridium difficile related diarrhea. Pathology 1996, 28:178-81.
13. Poxton IR, McCoubrey J, Blair G: The pathogenicity of Clostridium difficile. Clin Microbiol Infect 2001, 7:421-7.
14. Cohen SH, Tang YJ, Hansen B, Silva J Jr: Isolation of a toxin B-deficient mutant strain of Clostridium difficile in a case of recurrent C. difficile-associated diarrhea. Clin Infect Dis 1998, 26(2):410-2.
15. Tang-Feldman Y, Mayo S, Silva J Jr, Cohen SH: Molecular analysis of Clostridium difficile strains isolated from 18 cases of recurrent clostridium difficile-associated diarrhea. J Clin Microbiol 2003, 41:3413-3414.
16. Alonso R, Gros S, Pelaez T, Garcia-de-Viedma D, Rodriguez-Creixems M, Bouza E: Molecular analysis of relapse vs. re-infection in HIV-positive patients suffering from recurrent Clostridium difficile associated diarrhoea. J Hosp Infect 2001, 48:86-92.
17. Markowitz JE, Brown KA, Mamula P, Drott HR, Piccoli DA, Baldassano RN: Failure of single-toxin assays to detect clostridium difficile infection in pediatric inflammatory bowel disease. Am J Gastroenterol 2001, 96:2688-90.
18. Greenfield C, Aguilar Ramirez JR, Pounder RE, Williams T, Danvers M, Marper SR, Noone P: Clostridium difficile and inflammatory bowel disease. Gut 1983, 24:713-7.
19. Farrokhyar F, Swarbrick ET, Irvine EJ: A critical review of epidemiological studies in inflammatory bowel disease. Scand J Gastroenterol 2001, 36:2-15.
20. Demling L: Is Crohn's disease caused by antibiotics? Hepatogastroenterology 1994, 41:549-51.
21. Mahdavi J, Sonden B, Hurtig M, Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson KA, Altraja S, Wadstrom T, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson KE, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarstrom L, Boren T: Helicobacter pylori SabA adhesin in persistent infection and chronic inflammation. Science 2002, 297:573-8.
22. Wong SS, Woo PC, Luk WK, Yuen KY: Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999, 34(1):1-6.
23. Pelaez T, Sanchez R, Blazquez R, Catalan P, Munoz P, Bouza E: Abstr. 34th. Intersci. Conf. Antimicrob Agents Chemother 1994:50. abstr. E-34
24. Brazier JS, Fawley W, Freeman J, Wilcox MH: Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001, 48(5):741-2.
25. Drummond LJ, McCoubrey J, Smith DG, Starr JM, Poxton IR: Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J Med Microbiol 2003, 52(Pt 3):259-63.
26. Pituch H, Obuch-Woszczatynski P, Glinka D, Lazinska B, Meisel-Mikolajczyk F, Luczak M: Assessment of susceptibility to metronidazole and vancomycin of Clostridium difficile strains isolated between 1998-2002. Med Dosw Mikrobiol 2003, 55(3):253-8. Polish
27. Ackermann G, Degner A, Cohen SH, Silva J Jr, Rodloff AC: Prevalence and association of macrolide-lincosamide-streptogramin B (MLS(B)) resistance with resistance to moxifloxacin in Clostridium difficile. J Antimicrob Chemother 2003, 51(3):599-603.
28. Pinto LJ, Alcides AP, Ferreira EO, Avelar KE, Sabra A, Domingues RM, Ferreira MC: Incidence and importance of Clostridium difficile in paediatric diarrhoea in Brazil. J Med Microbiol 2003, 52(Pt 12):1095-9.
29. Jamal WY, Mokaddas EM, Verghese TL, Rotimi VO: In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int J Antimicrob Agents 2002, 20(4):270-4.
30. Alcantara CS, Guerrant RL: Update on Clostridium difficile infection. Curr Gastroenterol Rep 2000, 2:310-314.